BRPI1014760A2 - preparacao compreendendo insulina, nicotinamida e um aminoacido - Google Patents

preparacao compreendendo insulina, nicotinamida e um aminoacido

Info

Publication number
BRPI1014760A2
BRPI1014760A2 BRPI1014760A BRPI1014760A BRPI1014760A2 BR PI1014760 A2 BRPI1014760 A2 BR PI1014760A2 BR PI1014760 A BRPI1014760 A BR PI1014760A BR PI1014760 A BRPI1014760 A BR PI1014760A BR PI1014760 A2 BRPI1014760 A2 BR PI1014760A2
Authority
BR
Brazil
Prior art keywords
nicotinamide
insulin
preparation
amino acid
amino
Prior art date
Application number
BRPI1014760A
Other languages
English (en)
Inventor
Birk Olsen Helle
Naver Helle
Sturis Jeppe
Schlein Morten
Havelund Svend
Ludvigsen Svend
Ribel Ulla
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41351568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1014760(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BRPI1014760A2 publication Critical patent/BRPI1014760A2/pt
Publication of BRPI1014760A8 publication Critical patent/BRPI1014760A8/pt
Publication of BRPI1014760B1 publication Critical patent/BRPI1014760B1/pt
Publication of BRPI1014760B8 publication Critical patent/BRPI1014760B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BRPI1014760A 2009-06-26 2010-06-25 preparação compreendendo insulina, nicotinamida e arginina BRPI1014760B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09163940 2009-06-26
EP09163940.1 2009-06-26
US22216809P 2009-07-01 2009-07-01
US61/222,168 2009-07-01
PCT/EP2010/059069 WO2010149772A1 (en) 2009-06-26 2010-06-25 Preparation comprising insulin, nicotinamide and an amino acid

Publications (4)

Publication Number Publication Date
BRPI1014760A2 true BRPI1014760A2 (pt) 2017-07-18
BRPI1014760A8 BRPI1014760A8 (pt) 2018-01-09
BRPI1014760B1 BRPI1014760B1 (pt) 2021-04-13
BRPI1014760B8 BRPI1014760B8 (pt) 2021-05-25

Family

ID=41351568

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014760A BRPI1014760B8 (pt) 2009-06-26 2010-06-25 preparação compreendendo insulina, nicotinamida e arginina

Country Status (20)

Country Link
US (4) US8324157B2 (pt)
EP (2) EP2340033B1 (pt)
JP (2) JP5669834B2 (pt)
KR (1) KR101775000B1 (pt)
CN (2) CN104667264B (pt)
AU (1) AU2010264636B2 (pt)
BR (1) BRPI1014760B8 (pt)
CA (1) CA2764423A1 (pt)
DK (2) DK2340033T3 (pt)
ES (2) ES2440289T3 (pt)
HU (2) HUE027239T2 (pt)
IL (1) IL216520A (pt)
MX (1) MX2011012764A (pt)
NO (1) NO2017031I1 (pt)
PL (2) PL2340033T3 (pt)
PT (2) PT2612677E (pt)
RU (1) RU2533217C3 (pt)
TW (1) TWI459962B (pt)
WO (1) WO2010149772A1 (pt)
ZA (1) ZA201108942B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
KR101775000B1 (ko) * 2009-06-26 2017-09-04 노보 노르디스크 에이/에스 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제
CN103328006A (zh) * 2010-12-14 2013-09-25 诺沃—诺迪斯克有限公司 包含胰岛素、烟酰胺和氨基酸的制剂
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
GB201113880D0 (en) * 2011-08-12 2011-09-28 Archimed Llp Novel compositions
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
BR112014016195A2 (pt) 2011-12-30 2020-10-27 Halozyme, Inc. variantes de polipeptídio ph20, formulações e usos das mesmas
WO2013186138A1 (en) * 2012-06-14 2013-12-19 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and arginine
KR20150082640A (ko) 2012-11-13 2015-07-15 아도시아 치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
MX360420B (es) 2012-12-19 2018-10-31 Wockhardt Ltd Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma.
TWI641381B (zh) * 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
ES2804719T3 (es) * 2013-02-04 2021-02-09 Sanofi Sa Formulaciones farmacéuticas estabilizadas de análogos de insulina y/o derivados de insulina
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
KR20160104724A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형
WO2015120457A1 (en) * 2014-02-10 2015-08-13 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
US20170028031A1 (en) * 2014-03-07 2017-02-02 Klavs Holger Jørgensen Novel fast acting insulin preparations
JO3624B1 (ar) 2014-05-08 2020-08-27 Lilly Co Eli تركيبات إنسولين سريعة المفعول
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
ES2972423T3 (es) 2015-07-28 2024-06-12 Lilly Co Eli Preparado farmacéutico para mejorar la absorción y la acción hipoglucemiante postprandial de la insulina
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
GB201613895D0 (en) * 2016-08-12 2016-09-28 Arecor Ltd Novel composition
AU2017334290B2 (en) 2016-09-29 2023-04-20 Arecor Limited Novel formulations
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
WO2019193349A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
US20210113763A1 (en) 2018-04-04 2021-04-22 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
IL277721B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
FR3083984A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
US12102610B2 (en) 2018-09-18 2024-10-01 Eli Lilly And Company Treprostinil salt
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations
AR131148A1 (es) 2022-11-26 2025-02-19 Obshchestvo S Ogranichennoy Otvetstvennostyu «Geropharm» Composiciones de insulina de acción rápida (variantes de las mismas)
WO2024123214A1 (ru) 2022-12-04 2024-06-13 Общество С Ограниченной Ответственностью "Герофарм" Композиция инсулина аспарта (варианты)
TW202521158A (zh) * 2023-11-17 2025-06-01 大陸商上海藥明生物技術有限公司 用於高濃度蛋白製劑的降黏穩定製劑

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205126A (en) * 1978-01-01 1980-05-27 Cartaya Oscar A Serum-free cell culture media
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
ZA827928B (en) * 1981-10-30 1983-08-31 Novo Industri As Stabilized insulin preparations and process for preparation thereof
DE3313386A1 (de) * 1983-04-13 1984-10-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München Verfahren zur herstellung von nicht-brennbaren, thermisch isolierenden formkoerpern aus geblaehtem perlit
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
JP3122128B2 (ja) * 1989-12-21 2001-01-09 ノボ ノルディスク アクティーゼルスカブ ペプチド製剤
AU1272295A (en) 1993-12-17 1995-07-03 Novo Nordisk A/S Proinsulin-like compounds
RU2175556C2 (ru) * 1994-03-07 2001-11-10 Инхейл Терапьютик Системз Способы и композиции для легочной доставки инсулина
ZA954983B (en) 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
AU3562195A (en) * 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
IL118127A0 (en) 1995-05-05 1996-09-12 Lilly Co Eli Single chain insulin with high bioactivity
US6043092A (en) * 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
ZA984697B (en) * 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
SI0884053T1 (en) * 1997-06-13 2003-02-28 Eli Lilly And Company Stable insulin formulations
AU2001220765A1 (en) * 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US7115563B2 (en) 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
US20050232974A1 (en) 2004-04-19 2005-10-20 Gore Makarand P System and a method for pharmaceutical dosage preparation using jettable microemulsions
CA2649109A1 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
EP2404934A1 (en) 2006-09-22 2012-01-11 Novo Nordisk A/S Protease resistant insulin analogues
US8518668B2 (en) 2006-09-27 2013-08-27 Novo Nordisk A/S Method for making maturated insulin polypeptides in a fungal cell
JP5580050B2 (ja) 2006-12-15 2014-08-27 ティーマ ファウンデーション 組成物およびその使用
ES2558930T3 (es) * 2007-08-13 2016-02-09 Novo Nordisk A/S Análogos de la insulina de acción rápida
KR101775000B1 (ko) * 2009-06-26 2017-09-04 노보 노르디스크 에이/에스 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제

Also Published As

Publication number Publication date
JP2012530768A (ja) 2012-12-06
AU2010264636B2 (en) 2013-06-27
ES2440289T3 (es) 2014-01-28
IL216520A (en) 2017-08-31
JP5669834B2 (ja) 2015-02-18
DK2340033T3 (da) 2014-01-20
CN104667264B (zh) 2018-09-07
MX2011012764A (es) 2012-01-20
US20120135920A1 (en) 2012-05-31
KR20120047226A (ko) 2012-05-11
CA2764423A1 (en) 2010-12-29
TW201100093A (en) 2011-01-01
BRPI1014760B8 (pt) 2021-05-25
ZA201108942B (en) 2012-08-29
BRPI1014760A8 (pt) 2018-01-09
PL2340033T3 (pl) 2014-03-31
US20140206610A1 (en) 2014-07-24
EP2612677B1 (en) 2015-05-06
EP2612677A1 (en) 2013-07-10
US8324157B2 (en) 2012-12-04
US20150182595A1 (en) 2015-07-02
RU2533217C2 (ru) 2014-11-20
BRPI1014760B1 (pt) 2021-04-13
ES2543705T3 (es) 2015-08-21
IL216520A0 (en) 2012-02-29
TWI459962B (zh) 2014-11-11
RU2012100397A (ru) 2013-08-10
EP2340033B1 (en) 2013-10-09
AU2010264636A1 (en) 2012-01-12
PL2612677T3 (pl) 2015-10-30
CN102470165A (zh) 2012-05-23
NO2017031I1 (no) 2017-07-06
RU2533217C3 (ru) 2020-12-21
PT2340033E (pt) 2014-02-04
PT2612677E (pt) 2015-09-10
JP2015071608A (ja) 2015-04-16
CN102470165B (zh) 2014-12-24
KR101775000B1 (ko) 2017-09-04
HUE027239T2 (en) 2016-10-28
HUS1700027I1 (hu) 2017-07-28
DK2612677T3 (en) 2015-07-27
JP6026485B2 (ja) 2016-11-16
EP2340033A1 (en) 2011-07-06
CN104667264A (zh) 2015-06-03
US20130281364A1 (en) 2013-10-24
WO2010149772A1 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
BRPI1014760A2 (pt) preparacao compreendendo insulina, nicotinamida e um aminoacido
NO2024044I1 (no) Insulin icodec
IL280949A (en) Ph20 polypeptide variants, formulations and uses thereof
BR112013014856A2 (pt) preparação compreendendo insulina, nicotinamida e um aminoácido
IL244941A (en) Insulin preparations containing methionine
IL243932A0 (en) Certain chemical entities, compositions and methods
IL222930B (en) Chlorotoxin variants, conjugates and methods for their use
PL2403520T3 (pl) Preparaty insuliny do szybkiego wychwytu
ZA201008450B (en) Sweetener,methods of preparing sweetener and applications thereof
DK3590949T3 (da) Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf
HUE062860T2 (hu) Magas koncentrációjú gyógyszerészeti készítmények
BR112013013584A2 (pt) endoscópio, e, método
BRPI1010768A2 (pt) composto, e, composição farmacêutica.
DK3196309T3 (da) Thraustochytrider, fedtsyresammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
FI20096339L (fi) Liima-aine, menetelmä sen valmistamiseksi sekä sen käyttö
IL231444A0 (en) Aniline derivativs, their preparation and their therapeutic application
EP2415869A4 (en) MODIFIED OLIGO-NUCLEIC ACID MOLECULE, PROCESS FOR PREPARATION AND USES THEREOF
IL207202A0 (en) Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals
IL224367B (en) Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
DK2396056T3 (da) Insulinleveringssikkerhed
GB2488494B (en) Solution, use and method of preparation thereof
IL207204A0 (en) Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals
BR112014013189A8 (pt) método de fabricação de um cartão inteligente (`smartcard`) cartão inteligente, e cartão inteligente ( `smartcard`)
HRP20150021T1 (xx) Spojevi fenantrenona, pripravci i postupci
BR112012000294A2 (pt) preparação cosmética contendo ácido glicirretínico.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/06/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/06/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF